Melflufen: A Next-Generation Nitrogen Mustard

Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. December 09, 2020 ARTICLE CITATION DOI: 10.1200/JCO.20.03326 Journal of Clinical Oncology - published online before print January 13, 2021 PMID: 33439689 Melflufen: A Next-Generation Nitrogen Mustard Sarah A. Holstein , MD, PhD1xSarah A. HolsteinSearch for articles by this author; Jens Hillengass , MD2xJens HillengassSearch for articles by this author; and Philip L. McCarthy, MD2xPhilip L. McCarthySearch for articles by this author Show More 1Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE2Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY https://doi.org/10.1200/JCO.20.03326 First Page Full Text PDF Figures and Tables © 2021 by American Society of Clinical OncologyAUTHOR CONTRIBUTIONSConception and Design: All authorsCollection and assembly of data: Sarah A. Holstein, Philip L. McCarthyData analysis and interpretation: All authorsManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTMelflufen: A Next-Generation Nitrogen MustardThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Sarah A. HolsteinConsulting or Advisory Role: Celgene, Adaptive Biotechnologies, GlaxoSmithKline, Sorrento Therapeutics, Genentech, Takeda, Oncopeptides, SanofiResearch Funding: OncopeptidesJens HillengassEmployment: Roswell Park Cancer InstituteHonoraria: Amgen, Janssen Biotech, Takeda, Adaptive Biotechnologies, OncoTracker, GlaxoSmithKline, Bristol-Myers Squibb, SanofiResearch Funding: CelgeneTravel, Accommodations, Expenses: Amgen, Janssen Biotech, Rocket Medical, Celgene, Takeda, Adaptive Biotechnologies, Bristol-Myers SquibbPhilip L. McCarthyHonoraria: Celgene, Karyopharm Therapeutics, Bristol-Myers Squibb, Sanofi, Janssen, The Binding SiteConsulting or Advisory Role: Celgene, Bristol-Myers Squibb, Karyopharm Therapeutics, Sanofi, Janssen, The Binding Site, Magenta Therapeutics, Bluebird BioResearch Funding: CelgeneNo other potential conflicts of interest were reported.